John Strickler, MD

Articles

Dr. Strickler on Dosing Regorafenib in CRC

January 25th 2021

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Strickler on the Rationale for the MOUNTAINEER-02 Trial in HER2+ Gastric/GEJ Cancer

January 15th 2021

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

Dr. Strickler on Genomic Variants Detected by Liquid Biopsies in GI Cancers

April 4th 2019

John Strickler, MD, assistant professor of medicine, Duke Cancer Institute, discusses genomic variants that can be detected by liquid biopsies in patients with gastrointestinal cancers.

Dr. Strickler on Therapies for Rare Variants of Relapsed/Refractory CRC

March 13th 2019

John Strickler, MD, assistant professor of medicine at Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses therapies for rare variants of relapsed/refractory colorectal cancer.

Dr. Strickler on the Value of Liquid Biopsies in CRC

January 5th 2019

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses the value of liquid biopsies in the treatment of patients with colorectal cancer (CRC).

Dr. Strickler on Applications for Liquid Biopsies in GI Cancer

December 21st 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses applications for liquid biopsies in gastrointestinal cancer.

Dr. Strickler on the Importance of Molecular Markers in mCRC

December 6th 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses improvements in the treatment of metastatic colorectal cancer.